Followers | 1077 |
Posts | 26671 |
Boards Moderated | 12 |
Alias Born | 01/11/2016 |
Monday, September 19, 2022 8:41:05 PM
This one gets a little distraction, it will bleed slowly.
Recent SHPH News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 01:00:15 PM
- Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer • GlobeNewswire Inc. • 06/18/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 06/10/2024 10:12:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:15:20 PM
- Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 • GlobeNewswire Inc. • 05/22/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 01:00:22 PM
- Shuttle Pharma Provides First Quarter 2024 Corporate Update • GlobeNewswire Inc. • 05/14/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 09:01:59 PM
- Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024 • GlobeNewswire Inc. • 04/23/2024 08:15:00 PM
- Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update • PR Newswire (US) • 03/22/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 11:18:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 02:00:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 01:00:16 PM
- Shuttle Pharma Announces Its Intent to Pursue a Rights Offering • PR Newswire (US) • 02/13/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 09:25:13 PM
- Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 • PR Newswire (US) • 01/23/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 02:05:10 PM
- Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma • PR Newswire (US) • 01/08/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 10:10:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 02:51:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 10:10:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 02:00:12 PM
- Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma • PR Newswire (US) • 12/11/2023 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/30/2023 02:00:25 PM
- Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update • PR Newswire (US) • 11/14/2023 02:00:00 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM